<DOC>
	<DOCNO>NCT00697164</DOCNO>
	<brief_summary>Malaria remain one common life-threatening illness tropic dramatic toll one million deaths year . A majority malaria case non-complicated evolve towards severe malaria result combination parasite-specific virulence factor host inflammatory response . Cerebral malaria ( CM ) kill 1 million African child year . CM carry fatality rate 20 % adult , high child , despite timely adequate chemotherapy . Moreover , rapid clearance parasitaemia new antimalarial drug associate improved survival , suggest potential interest adjunctive therapy early phase disease . Cerebral malaria lead seizure coma associate severe intracranial hypertension cause brain-swelling . Recent image post-mortem finding adult cerebral malaria confirm presence diffuse cerebral oedema thalamic cerebellar white matter hypoattenuation , diffuse petechial hemorrhage symmetric ischemic change involve thalamus cerebellum . However , nature pathogenetic process lead cerebral malaria incompletely understood mechanism link cytokine endothelial cell activation cerebral microvasculature recently stress . The effect new neuroprotective therapy yet investigate , although manifestation cerebral malaria partly share feature neurological stroke acute non-specific neurological disorder . The hormone erythropoietin ( EPO ) probably one enthusiastic drug area . EPO member type I cytokine superfamily multiple function , include prominent role erythropoiesis neuroprotection . Systematically administer EPO cross blood brain barrier via abundant expression EPO receptor brain capillary , act anti-apoptotic cytoprotective cytokine . Moreover , EPO prevent inflammation inhibit pro-inflammatory cytokine include TNFÎ± , preserve endothelial cell integrity prevent blood-brain barrier permeability . We propose randomized clinical trial investigate safety efficacy EPO patient present cerebral malaria hospitalize Gabriel Toure hospital , Bamako , Mali , reduce incidence premature death hospitalize patient .</brief_summary>
	<brief_title>Randomized Trial Erythropoietin During Cerebral Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Cerebral</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Children 6 month 14 year old Severe cerebral malaria due Plasmodium falciparum Coma ( Blantyre score &lt; 3 ) Enlightened assessment Any case participation refusal Presence another obvious affection able explain state patient Negative malaria test ( thick smear / thin smear ) Severe anaemia</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Treatment</keyword>
	<keyword>Adjunctive</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Survival</keyword>
</DOC>